GlassScriptPhysician profile
Kristen P Hook
NPI 1053465641
$960.20
in general payments reported to CMS, 2019-2025
20 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $50.50 · 2022: $34.43 · 2023: $266 · 2024: $164 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $319.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $110.81 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $99.39 | 2019-2023 | |
| Leo Pharma INC. | $70.89 | 2023-2025 | Adbry |
| Blueprint Medicines Corporation | $59.83 | 2023 | |
| Incyte Corporation | $55.09 | 2023-2024 | Opzelura |
| Dermavant Sciences, INC. | $33.06 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $31.87 | 2023 | Odomzo |
| Dermira, INC. | $28.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.49 | 2023 | Spevigo |
| Amgen INC. | $18.48 | 2025 | Otezla |
| Celgene Corporation | $16.38 | 2019 | |
| Galderma Laboratories, L.P. | $16.37 | 2024 | |
| Lilly USA, LLC | $16.23 | 2024 | Taltz |
| Biofrontera INC. | $14.59 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $14.07 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $13.51 | 2024 | Ycanth |
| Smith+Nephew, INC. | $13.14 | 2024 | Collagenase Santyl |
| Pierre Fabre Pharmaceuticals, INC. | $6.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Hook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.